TRIB3 and hepatocellular carcinoma: To test whether induction of TRIB3 by sorafenib is dependent on in vivo cancer environments, we directly subjected hepatoma cell lines—Huh‐7, MHCC‐97H, Hep G2, and SNU‐449—to sorafenib in vitro.